Although these preliminary findings require further validation of specific isoforms, they suggest that pediatric sarcomas may express splicing variants of full-length RON (flRON) that evade targeting strategies based on interruption of ligand–receptor binding, such as IMC-RON8. This evidence concerns the gene MST1R and sarcoma.